Welcome to our dedicated page for COHBAR news (Ticker: CWBR), a resource for investors and traders seeking the latest updates and insights on COHBAR stock.
CohBar Inc. (NASDAQ: CWBR) is a pioneering biotechnology company dedicated to transforming the way we approach chronic and age-related diseases. By harnessing the power of mitochondria through its innovative Mitochondria-Based Therapeutics (MBTs), the company is opening new frontiers in treating conditions that currently have limited or no treatment options.
CohBar's core business revolves around the discovery and development of therapeutic peptides encoded within the mitochondrial genome. These peptides, discovered by the company's founding scientists who are leaders in the fields of aging, metabolism, and mitochondrial genomics, have shown promise in addressing a wide array of diseases including type 2 diabetes, cancer, atherosclerosis, and neurodegenerative disorders.
Currently, CohBar is in the clinical-stage of development with several exciting projects in its pipeline. The company's most recent achievements include successful advancements in clinical trials and ongoing research into new peptide candidates. Financially, CohBar remains committed to maintaining a robust cash position to support its research and development activities.
Partnerships play a crucial role in CohBar's strategy. The company collaborates with leading academic institutions and other biotech firms to enhance its research capabilities and expedite the development of its therapeutic candidates.
Recent news highlights include the summary and financial results for the second quarter of 2023, showcasing CohBar's continuous progress and commitment to its mission. The company has also announced a proposed merger with Morphogenesis, which is expected to create significant synergies and enhance the combined entity's market presence.
For more detailed information about CohBar, its projects, and recent updates, visit their official website or follow them on LinkedIn. Investors are encouraged to contact the company directly at investors@cohbar.com for further inquiries.
CohBar, Inc. (NASDAQ: CWBR) reported its Q3 2022 financial results, highlighting a net loss of $2.4 million, or $0.82 per share, improving from a $3.4 million loss in Q3 2021. Cash reserves stood at $18.3 million, down from $26.2 million at year-end 2021, with a quarterly cash burn of approximately $1.9 million. Key developments included the ongoing formulation work for CB5138-3 aimed at idiopathic pulmonary fibrosis (IPF) and the successful completion of a 1-for-30 reverse stock split to comply with Nasdaq requirements. The company appointed Dr. Effie Tozzo to its board, enhancing its strategic expertise.
CohBar, Inc. (NASDAQ: CWBR) will release its 2022 Q3 financial results on November 8, 2022, after market close. The company's management will host a conference call at 5:00 p.m. ET to discuss the results and provide business updates. CohBar is focused on developing therapeutics for chronic and age-related diseases through its innovative Mito+ platform. They plan to file an IND for clinical candidate CB5138-3 targeting idiopathic pulmonary fibrosis in the second half of 2023. The company previously showcased clinical proof of concept for CB4211 for NASH and obesity.
CohBar, Inc. (NASDAQ: CWBR) announced a 1-for-30 reverse stock split effective September 23, 2022, to comply with Nasdaq's $1.00 minimum bid price requirement. This decision follows stockholder approval at the June 15, 2022, Annual Meeting. As a result, every 30 shares will convert into one share, with cash payments for any fractional shares. The company also increased the number of authorized shares to approximately 12,000,000. The reverse stock split will apply uniformly across all stockholders, impacting outstanding stock options and warrants proportionately.
CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology firm, announced its CEO, Dr. Joseph Sarret, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will detail CohBar's innovative approach to developing therapeutics targeting chronic and age-related diseases using mitochondrial peptides. A replay of the webcast will be accessible on the company's website for two weeks following the event. CohBar aims to file an IND for its second clinical candidate by late 2023, focusing initially on idiopathic pulmonary fibrosis.
CohBar, Inc. (NASDAQ: CWBR) reported its Q2 2022 financial results and business progress on August 15, 2022. The company is on track to file an Investigational New Drug (IND) application for its lead program, CB5138-3, targeting Idiopathic Pulmonary Fibrosis (IPF) in H2 2023. CohBar strengthened its IPF program with expanded patent coverage for CB4211 and appointed Dr. Effie Tozzo to its board. The company’s cash reserves stand at $20.1 million as of June 30, 2022, down from $26.2 million. R&D and G&A expenses decreased, contributing to a net loss of $2.7 million, or $0.03 per share.
FAQ
What is the current stock price of COHBAR (CWBR)?
What is the market cap of COHBAR (CWBR)?
What does CohBar Inc. specialize in?
What are Mitochondria-Based Therapeutics (MBTs)?
Who founded CohBar Inc.?
What recent achievements has CohBar made?
What diseases are targeted by CohBar’s therapies?
Is CohBar financially stable?
How does CohBar collaborate with other entities?
What is the significance of the proposed merger with Morphogenesis?
How can investors get in touch with CohBar?
Where can I find more information about CohBar?
